Financial Performance - Silexion raised over $9 million in gross funds during Q1 2025, strengthening its financial position[1] - The company reported a net loss of $1.7 million for Q1 2025, compared to a net loss of $1.4 million in Q1 2024, primarily due to increased general and administrative expenses[7] - Cash and cash equivalents increased to $6.2 million as of March 31, 2025, up from $1.2 million as of December 31, 2024[7] - Total operating expenses for Q1 2025 were $1.7 million, an increase from $1.3 million in the same period of 2024[7] - Research and development expenses decreased to $0.6 million in Q1 2025 from $1.0 million in Q1 2024, reflecting reduced subcontractor costs[7] - Total assets increased to $8.3 million as of March 31, 2025, compared to $2.9 million as of December 31, 2024[9] Product Development - SIL204 demonstrated a ~70% reduction in tumor cell numbers in the AsPC-1 model and ~80% reduction in the BxPC-3 model by day 28 in preclinical studies[3] - The company unveiled an expanded dual-route development strategy for SIL204, targeting both primary tumors and metastases, with clinical trials planned to start in the first half of 2026[3] - Silexion announced a strategic collaboration with Catalent for formulation development and clinical manufacturing activities for SIL204[3] - The company completed a public offering raising approximately $5.0 million in gross proceeds during Q1 2025[3]
Silexion Therapeutics Corp(SLXN) - 2025 Q1 - Quarterly Results